Halozyme Therapeutics (HALO) is back in focus after announcing a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon technology, a deal that includes a US$15 million upfront payment.

The Vertex agreement comes as Halozyme’s share price shows renewed momentum, with a 7 day share price return of 5.16% and a 30 day share price return of 6.53%, while the 1 year total shareholder return sits at 12.62% and the 3 year total shareholder return at 90.24%. This comes even after a 6.35% decline over 90 days and a 3.54% year to date share price pullback.

If this kind of licensing news has your attention, it can be worth widening your search to other healthcare names using a screener focused on 31 healthcare AI stocks

With Halozyme trading at US$67.82 and an analyst price target of US$84.89, plus an indicated intrinsic value gap, the key question is whether this licensing momentum signals an undervalued platform or if the market is already factoring in future growth.

Most Popular Narrative: 19.7% Undervalued

Against the last close of $67.82, the most followed narrative anchors Halozyme’s fair value at $84.50 and frames the Vertex collaboration within a broader pipeline and royalty story.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (e.g., DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Want to see what kind of revenue, margin and earnings path backs that $84.50 fair value? The narrative leans on ambitious growth, rising profitability and a lower future earnings multiple than many peers.

Result: Fair Value of $84.50 (UNDERVALUED)

However, you still need to weigh regulatory and reimbursement uncertainty, plus Halozyme’s reliance on a few major royalty partners, which could challenge that 19.7% undervalued case.

Another View: Multiples Flash a Very Different Signal

That 19.7% undervalued fair value hinges on future cash flows, but the current market snapshot tells a tougher story. Halozyme trades on a P/E of 25.4x versus 20x for peers, and a fair ratio of 18.4x, which points to valuation risk rather than an obvious bargain. Which signal do you trust more right now?

Before leaning too heavily on one view, it can help to see how this P/E gap stacks up against other companies in similar situations, and what that might imply if the market drifts toward the fair ratio over time. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and sentiment running both hot and cold, it makes sense to move quickly and weigh the full picture yourself by checking the 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If Halozyme has sharpened your focus, do not stop here. The screener can surface other opportunities that might fit your style before the market fully catches on.

• Target resilience by checking companies on the 72 resilient stocks with low risk scores that aim to balance return potential with controlled risk scores.
• Hunt for quality at a reasonable price by using the 58 high quality undervalued stocks to see which businesses combine solid fundamentals with potentially attractive valuations.
• Spot dependable income ideas by scanning the 11 dividend fortresses that highlight higher yielding names aiming to pair stability with regular payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.